There is our positive response from the FDA, explaining the buying prior to the halt.
No company puts entity into a trading halt for negative FDA responses, those do not require such steps. Since these news are far reaching not only for our first program but in consequence for the entire pipeline, insider trading of a leaky ship needs to be avoided, hence the halt.
It has been a lengthy wait with plenty of delays to reach the status of an asset company within clinical trials but I am very confident for this to be well worth the invested time and funds by many long term investors. We will be also one step closer for those patients participating in the upcoming trials or those waiting for approval and market entry to have a treatable option for this debilitating condition.
I look forward to the coming months and early readouts, all IMO
PYC Price at posting:
8.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)